Fifteen Years of Clinical Trials in Huntington’s Disease: A Very Low Clinical Drug Development Success Rate
- 30 June 2017
- journal article
- Published by SAGE Publications in Journal of Huntington's Disease
- Vol. 6 (2) , 157-163
Abstract
Background: Drug development in Huntington’s disease (HD) is particularly challenging, and only two compounds are approved by the FDA. It is therefore essential to appraise drug development programs in order to understand the reasons for their failurKeywords
This publication has 21 references indexed in Scilit:
- Survival, Mortality, Causes and Places of Death in a European Huntington's Disease Prospective CohortMovement Disorders Clinical Practice, 2017
- When are clinical trials registered? An analysis of prospective versus retrospective registrationTrials, 2016
- The Prevalence of Huntington's DiseaseNeuroepidemiology, 2016
- Huntington diseaseNature Reviews Disease Primers, 2015
- Update on Huntington's disease: Advances in care and emerging therapeutic optionsParkinsonism & Related Disorders, 2015
- Huntington's disease: An update of therapeutic strategiesGene, 2015
- Characteristics of clinical trial websites: information distribution between ClinicalTrials.gov and 13 primary registries in the WHO registry networkTrials, 2014
- Huntington disease: natural history, biomarkers and prospects for therapeuticsNature Reviews Neurology, 2014
- The incidence and prevalence of Huntington's disease: A systematic review and meta‐analysisMovement Disorders, 2012
- The ClinicalTrials.gov Results Database — Update and Key IssuesNew England Journal of Medicine, 2011